Eric Hsu
Corporate Officer/Principal chez INMED PHARMACEUTICALS INC.
Fortune : 19 $ au 31/03/2024
Profil
Eric C.
Hsu is currently the Vice President-Preclinical Research & Development at InMed Pharmaceuticals, Inc. Prior to this, he worked at enGene, Inc. for 16 years as the VP-Scientific Affairs, Research & Operations.
He completed his undergraduate degree at McGill University and received his doctorate from the University of Toronto in 1999.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 04/03/2024 | 51 ( 0,00% ) | 19 $ | 31/03/2024 |
Postes actifs de Eric Hsu
| Sociétés | Poste | Début |
|---|---|---|
| INMED PHARMACEUTICALS INC. | Corporate Officer/Principal | 13/03/2018 |
Anciens postes connus de Eric Hsu
| Sociétés | Poste | Fin |
|---|---|---|
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Chief Operating Officer | 01/01/2018 |
Formation de Eric Hsu
| McGill University | Undergraduate Degree |
| University of Toronto | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INMED PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
